PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL

Oncogene

Volumn 28, Issue 46, 2009, Pages 4116-4125

  Ueno, S ^a   Tatetsu, H ^a   Hata, H ^a   Iino, T ^b,c   Niiro, H ^b   Akashi, K ^b,c   Tenen, D G ^c,d   Mitsuya, H ^a   Okuno, Y ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Apoptosis; Myeloma; P21; PU.1; TRAIL

Indexed keywords

CYCLIN A2; CYCLIN B1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; PROTEIN P21; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR PU 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN FUNCTION; TRANSACTIVATION;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON REGULATORY FACTOR-7; INTERFERON REGULATORY FACTORS; INTERFERONS; MULTIPLE MYELOMA; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION;

EID: 70450267416     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.263     Document Type: Article

References (33)

1. Amaravadi L, Klemsz MJ. (1999). DNA methylation and chromatin structure regulate PU.1 expression. DNA Cell Biol 18: 875-884.
2. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. (2003). Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349: 2495-2502.
3. Coccia EM, Del Russo N, Stellacci E, Orsatti R, Benedetti E, Marziali G et al. (1999). Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2. Oncogene 18: 2129-2137.
4. de Veer MJ, Sim H, Whisstock JC, Devenish RJ, Ralph SJ. (1998). IFI60/ISG60/IFIT4, a new member of the human IFI54/IFIT2 family of interferon-stimulated genes. Genomics 54: 267-277.
5. Gazitt Y. (1999). TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13: 1817-1824.
6. Hideshima T, Richardson P, Anderson KC. (2003). Novel therapeutic approaches for multiple myeloma. Immunol Rev 194: 164-176. (Pubitemid 36886435)
7. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. (2001). The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076.
8. Huang G, Zhang P, Hirai H, Elf S, Yan X, Chen Z et al. (2008). PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet 40: 51-60.
9. Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B et al. (1997). Deregulation of MUM1/IRF4 by chromosomal transloca-tion in multiple myeloma. Nat Genet 17: 226-230.
10. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. (2005). Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76.
11. Kirshner JR, Karpova AY, Kops M, Howley PM. (2005). Identification of TRAIL as an interferon regulatory factor 3 transcriptional target. J Virol 79: 9320-9324.
12. Klein U, Casola S, Cattoretti G, Shen Q, Lia M, Mo T et al. (2006). Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 7: 773-782.
13. Klemsz MJ, McKercher SR, Celada A, Van Beveren C, Maki RA. (1990). The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell 61: 113-124.
14. Li Y, Okuno Y, Zhang P, Radomska HS, Chen H, Iwasaki H et al. (2001). Regulation of the PU.1 gene by distal elements. Blood 98: 2958-2965.
15. Loots GG, Locksley RM, Blankespoor CM, Wang ZE, Miller W, Rubin EM et al. (2000). Identification of a coordinate regulator of interleukins 4, 13, and 5 by cross-species sequence comparisons [see comments]. Science 288: 136-140.
16. Mariani SM, Matiba B, Armandola EA, Krammer PH. (1997). Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol 137: 221-229.
17. McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H et al. (1996). Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. Embo J 15: 5647-5658.
18. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R et al. (2001). TRAIL/Apo2 L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98: 795-804.
19. Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. (2002). Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 99: 2162-2171. (Pubitemid 34525502)
20. Moreau-Gachelin F, Tavitian A, Tambourin P. (1988). Spi-1 is a putative oncogene in virally induced murine erythroleukaemias. Nature 331: 277-280.
21. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P et al. (2005). Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11: 77-84.
22. Okuno Y, Huang G, Rosenbauer F, Evans EK, Radomska HS, Iwasaki H et al. (2005). Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol Cell Biol 25: 2832-2845.
23. Okuno Y, Huettner CS, Radomska HS, Petkova V, Iwasaki H, Akashi K et al. (2002a). Distal elements are critical for human CD34 expression in vivo. Blood 100: 4420-4426.
24. Okuno Y, Iwasaki H, Huettner CS, Radomska HS, Gonzalez DA, Tenen DG et al. (2002b). Differential regulation of the human and murine CD34 genes in hematopoietic stem cells. Proc Natl Acad Sci USA 99: 6246-6251.
25. Pahl HL, Scheibe RJ, Zhang DE, Chen HM, Galson DL, Maki RA et al. (1993). The proto-oncogene PU.1 regulates expression of the myeloid-specific CD11b promoter. J Biol Chem 268: 5014-5020.
26. Radomska HS, Gonzalez DA, Okuno Y, Iwasaki H, Nagy A, Akashi K et al. (2002). Transgenic targeting with regulatory elements of the human CD34 gene. Blood 100: 4410-4419.
27. Rosenbauer F, Owens BM, Yu L, Tumang JR, Steidl U, Kutok JL et al. (2006). Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet 38: 27-37.
28. Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, Okuno Y et al. (2004). Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 36: 624-630.
29. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. (2008). IRF4 addiction in multiple myeloma. Nature 454: 226-231.
30. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. (1999). Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571.
31. Tatetsu H, Ueno S, Hata H, Yamada Y, Takeya M, Mitsuya H et al. (2007). Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res 67: 5328-5336.
32. Tenen DG. (2003). Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3: 89-101.
33. Yu W, Misulovin Z, Suh H, Hardy RR, Jankovic M, Yannoutsos N et al. (1999). Coordinate regulation of RAG1 and RAG2 by cell type-specific DNA elements 50 of RAG2. Science 285: 1080-1084.